Beatrice Mutayoba
Overview
Explore the profile of Beatrice Mutayoba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamori D, Barabona G, Maokola W, Rugemalila J, Mahiti M, Mizinduko M, et al.
PLoS One
. 2024 Aug;
19(8):e0307003.
PMID: 39141647
Background: Tanzania has made significant progress in improving access to HIV care and treatment. However, virologic suppression among people living with HIV (PLHIV) has not been fully realized. In March...
2.
Mghamba J, Gilmour E, Robinson L, Simba A, Tuyishime A, Persaud A, et al.
Front Public Health
. 2023 May;
11:1115415.
PMID: 37181718
This article is part of the Research Topic 'Health Systems Recovery in the Context of COVID-19 and Protracted Conflict'. The COVID-19 pandemic has exposed the vulnerabilities and limitations of many...
3.
Steinmann P, Cavaliero A, Aerts A, Anand S, Arif M, Ay S, et al.
Lepr Rev
. 2023 May;
89(2):102-116.
PMID: 37180343
Innovative approaches are required to further enhance leprosy control, reduce the number of people developing leprosy, and curb transmission. Early case detection, contact screening, and chemoprophylaxis currently is the most...
4.
Rugemalila J, Kamori D, Kunambi P, Mizinduko M, Sabasaba A, Masoud S, et al.
PLoS One
. 2023 Feb;
18(2):e0281528.
PMID: 36821538
Background: The emergence of HIV drug resistance mutations (DRMs) is of significant threat to achieving viral suppression (VS) in the quest to achieve global elimination targets. We hereby report virologic...
5.
Kamori D, Barabona G, Rugemalila J, Maokola W, Masoud S, Mizinduko M, et al.
J Antimicrob Chemother
. 2023 Jan;
78(3):779-787.
PMID: 36680436
Background: Despite the scale-up of ART and the rollout in Tanzania of dolutegravir, an integrase strand transfer inhibitor (INSTI), treatment success has not been fully realized. HIV drug resistance (HIVDR),...
6.
Kilale A, Makasi C, Majaha M, Manga C, Haule S, Hilary P, et al.
BMC Public Health
. 2022 Nov;
22(1):2187.
PMID: 36434606
Tuberculosis (TB) disproportionally affects persons and families who are economically and socially disadvantaged. Therefore, a patient cost survey was conducted in Tanzania to evaluate the costs incurred by patients and...
7.
Bachanas P, Chun H, Mehta N, Aberle-Grasse J, Parris K, Sherlock M, et al.
J Int AIDS Soc
. 2022 Nov;
25(11):e26033.
PMID: 36419346
Introduction: The potential disruption in antiretroviral therapy (ART) services in Africa at the start of the COVID-19 pandemic raised concern for increased morbidity and mortality among people living with HIV...
8.
Kalolo A, Lalashowi J, Pamba D, Shayo P, Gitige C, Mvungi H, et al.
BMJ Open
. 2022 May;
12(5):e054434.
PMID: 35613774
Introduction: Tanzania is adapting a shortened injectable-free multidrug resistant tuberculosis (MDR-TB) regimen, comprising new drugs such as bedaquiline and delamanid and repurposed drugs such as clofazimine and linezolid. The regimen...
9.
Kilale A, Pantoja A, Jani B, Range N, Ngowi B, Makasi C, et al.
BMC Public Health
. 2022 Mar;
22(1):600.
PMID: 35351063
Background: Although tuberculosis (TB) care is free in Tanzania, TB-associated costs may compromise access to services and treatment adherence resulting in poor outcomes and increased risk of transmission in the...
10.
Rugemalila J, Kamori D, Maokola W, Mizinduko M, Barabona G, Masoud S, et al.
BMJ Open
. 2021 Dec;
11(12):e054021.
PMID: 34921085
Introduction: Tanzania is making an enormous effort in scaling-up of antiretroviral therapy (ART). However, people living with HIV (PLHIV) continue to succumb to the challenge of drug resistance. Evidence on...